PROJECTS
Evidence across materials, mechanisms and products
A2P2 has been applied across medical-device and adjacent regulated-product environments, including sterile barrier packaging, biopharmaceutical single-use systems, implantable polymers, biopolymers, collagen and bovine pericardium, gamma-irradiated assemblies, adhesives, tubing and industrial membrane systems.
4
INDEPENDENT STUDIES
3
POLYMER FAMILIES
2
LABORATORIES
8 yrs
FIELD SERVICE COMPARED
THE PURPOSE OF EVERY DEPLOYMENT IS THE SAME
1Identify the governing behaviour
2Design the right experiment
3Calculate a defensible time equivalence
4Connect the result to a decision the organisation can explain
WHERE A2P2 HAS BEEN APPLIED
From implantable devices to industrial membranes

MEDICAL DEVICES
Pacemakers

MEDICAL DEVICES
Vascular grafts

BIOMATERIALS
Bovine pericardium
BIOMATERIALS
Biopolymers & collagen
Bio-derived materials alongside synthetic polymers

MEDICAL DEVICES
IV bags

DRUG DELIVERY
COC syringes
DRUG DELIVERY
Vial adapters

ASSEMBLIES
Fluid-path assemblies

PACKAGING
Sterile barrier packaging

PACKAGING
Thermoformed trays

BIOPHARMA
Single-use bioprocess bags

BIOPHARMA
Silicone tubing manifolds

BIOPHARMA
Braided transfer tubing

BIOPHARMA
FEP-lined reinforced hoses

BIOPHARMA
Capsule filters

BIOPHARMA
Filtration membranes

INDUSTRIAL
Reverse osmosis membranes
ACROSS SECTORS
Gamma-irradiated assemblies & adhesives
Plus multilayer films, elastomers and implantable polymers
Deployments are confidential by default. The summaries below are anonymised. Study designs, source data and detailed outputs are available only where disclosure is authorised or under NDA.
VALIDATION EVIDENCE
Tested against independent evidence
Four independent studies · three polymer families · two laboratories
RETRO-1EXTERNAL LITERATURE
Medical-grade polyurethane
Hydrolysis · Arrhenius fit
A2P2 PREDICTION
Ea = 42.4 kJ/mol
PUBLISHED REFERENCE
Ea ≈ 42 kJ/mol
r² = 1.000
Within ±10% Ea criterion
RETRO-2INDUSTRY PU ELASTOMER
Poly(ether)urethane
Concurrent hydrolysis + ageing
HYDROLYSIS Ea
91.2 kJ/mol
PHYSICAL AGEING Ea
163–200 kJ/mol
9 days at 50°C ≡ 4 years at 37°C
Concurrent mechanisms integrated
RETRO-3STERILE BARRIER PACKAGING
PET tray + sealing film
System-level physical ageing
TRAY
Ea > 300 kJ/mol · Q10 ≈ 10
FILM
Ea ≈ 118 kJ/mol · Q10 ≈ 4
Assembly Q10 ≈ 7
9–12 months validation time saved
PROSP-1FIELD REAL-TIME
PA/PSU/PET composite membrane
8-year continuous service
A2P2 PREDICTION
0.9%/year rejection loss
FIELD OBSERVATION
0.875–0.9%/year confirmed
95% prediction limit overlap met
Cross-material anchor established
Cross-material reproducibility confirmed across three chemically distinct polymer families: poly(ether)urethane, PET assembly and PA/PSU/PET composite, across two independent laboratories and five independent datasets.
±10% Ear² ≥ 0.9595% prediction limit overlap
Currently under FDA MDDT review
Referenced in active ASTM F1980 revision
SELECTED OUTCOMES
What the evidence changed
337 → 71 days
AGEING PATHWAY
Bioreactor stability programme
A material-specific A2P2 programme reduced an ageing pathway from 337 days to 71 days while retaining an explicit scientific basis for the acceleration conditions and verification plan.
≈ £40M
AVOIDED WASTE
Adhesive shelf-life extension
A2P2 supported an evidence-led shelf-life extension associated with approximately £40 million in avoided waste. The work focused on the governing adhesive behaviour rather than treating the full assembly as a uniform ageing system.
8 years
CONTINUOUS FIELD SERVICE
Membrane field validation
A2P2 predictions for a polyamide composite separation membrane were evaluated against eight years of continuous service in pharmaceutical-grade water operation, providing a long-duration comparison between accelerated prediction and field behaviour.
Extended
OPERATIONAL LIFE
Tubing life-cycle programme
A combined cleaning, drying, inspection and performance-verification programme extended operational tubing life beyond the original replacement interval while maintaining defined acceptance criteria.
DISCUSS THE RELEVANT EVIDENCE
Request an anonymised technical discussion
Qualified organisations can request an anonymised technical discussion under NDA.
TESTED AGAINST INDEPENDENT EVIDENCE

